[转移性直肠癌的缓解治疗]
Thomas Seufferlein1, Thomas Jens Ettrich1
1Klinik für Innere Medizin I, Universitätsklinikum Ulm, Ulm, Deutschland.
Zentralblatt fur Chirurgie
|March 5, 2024
概括
转移性结直肠癌 (mCRC) 息治疗的最新进展包括针对特定患者群体的新疗法和分子定义的策略. 本文概述了基于证据的治疗选择和临床算法.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 转移性结直肠癌 (mCRC) 管理已经显著发展.
- 息护理策略越来越复杂.
研究的目的:
- 为mCRC提供基于证据的治疗选择.
- 在mCRC中概述目前的息护理治疗算法.
主要方法:
- 审查最近的治疗策略.
- 对治疗选择的证据综合.
- 开发用于临床应用的算法.
主要成果:
- 引入和维持疗法的引入.
- 针对性的治疗方法的整合.
- 针对MSI-H子组的个性化策略.
结论:
- 目前的息性mCRC治疗提供了各种各样的,基于证据的选择.
- 治疗算法指导个性化患者护理.
- 进展侧重于有针对性和分子定义的方法.
更多相关视频
相关概念视频
Peptic Ulcer Disease IV: Management
92
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92
Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169


